# EDGAR Filing Document

**Accession Number:** 0001662817
**File Stem:** 0001213900-25-085116
**Filing Date:** 2025-9
**Character Count:** 17390
**Document Hash:** 151b3937b5a03edc914268f12105cf20
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-085116.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001213900-25-085116

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250905

**DATE AS OF CHANGE**: 20250905

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** STRATA Skin Sciences, Inc.
- **CENTRAL INDEX KEY:** 0001051514
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133986004
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-81125
- **FILM NUMBER:** 251297377

**BUSINESS ADDRESS:**
- **STREET 1:** 5 WALNUT GROVE DRIVE
- **STREET 2:** SUITE 140
- **CITY:** HORSHAM
- **STATE:** PA
- **ZIP:** 19044
- **BUSINESS PHONE:** 215-619-3200

**MAIL ADDRESS:**
- **STREET 1:** 5 WALNUT GROVE DRIVE
- **STREET 2:** SUITE 140
- **CITY:** HORSHAM
- **STATE:** PA
- **ZIP:** 19044

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MELA SCIENCES, INC. /NY
- **DATE OF NAME CHANGE:** 20100504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ELECTRO OPTICAL SCIENCES INC /NY
- **DATE OF NAME CHANGE:** 19971216
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Accelmed Partners, L.P.
- **CENTRAL INDEX KEY:** 0001662817

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 6 HACHOSHLIM STREET, 6TH FLOOR
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 4672406
- **BUSINESS PHONE:** 972-9-788-5599

**MAIL ADDRESS:**
- **STREET 1:** 6 HACHOSHLIM STREET, 6TH FLOOR
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 4672406

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Accelmed Growth Partners, L.P.
- **DATE OF NAME CHANGE:** 20160105

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**STRATA Skin Sciences**

*(Name of Issuer)*

**Common stock, $0.001 par value per share**

*(Title of Class of Securities)*

**86272A305**

*(CUSIP Number)*

**Accelmed Partners, L.P.**<br>1670 Daytonia Road<br>Attn: Uri Geiger<br>Miami Beach FL 33141<br>(786) 826-9118

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/04/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **86272A305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Accelmed Partners, L.P.** | Name of reporting person<br>**Accelmed Partners, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1441835.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1441835.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**27.4%** | Percent of class represented by amount in Row (11)<br>**27.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

| **CUSIP No.** | **86272A305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Accelmed Partners (GP), L.P.** | Name of reporting person<br>**Accelmed Partners (GP), L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1441835.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1441835.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**27.4%** | Percent of class represented by amount in Row (11)<br>**27.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

| **CUSIP No.** | **86272A305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Accelmed Growth Partners (AGP) Ltd.** | Name of reporting person<br>**Accelmed Growth Partners (AGP) Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1441835.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1441835.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**27.4%** | Percent of class represented by amount in Row (11)<br>**27.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

| **CUSIP No.** | **86272A305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Accelmed Growth Partners Management Ltd.** | Name of reporting person<br>**Accelmed Growth Partners Management Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1441835.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1441835.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**27.4%** | Percent of class represented by amount in Row (11)<br>**27.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

| **CUSIP No.** | **86272A305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Uri Geiger** | Name of reporting person<br>**Uri Geiger** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1441835.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1441835.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | Aggregate amount beneficially owned by each reporting person<br>**1441835.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**27.4%** | Percent of class represented by amount in Row (11)<br>**27.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" below.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common stock, $0.001 par value per share

**(b) Name of Issuer:**
STRATA Skin Sciences

**(c) Address of Issuer's Principal Executive Offices:**
5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM, PA, 19044

Explanatory Note

This Amendment No. 2 to Schedule 13D (this "Schedule 13D/A") is being filed to amend the Schedule 13D filed with the U.S. Securities and Exchange Commission ("SEC") on April 3, 2018, as amended on July 18, 2024 (together, the "Initial 13D"). The Reporting Persons are filing this 13D/A solely to report a change in percent of class due to the September 4, 2025 issuance by Strata Skin Sciences, Inc. of 1,097,547 shares of Common Stock in a registered direct offering to third party investors (the "Offering"). Upon closing of the Offering, there are a total of 5,268,708 shares of Common Stock outstanding. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Initial 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See rows (11) and (13) of the cover pages to this Schedule 13D/A for the aggregate number of shares of Common Stock and percentages beneficially owned by each of the Reporting Persons. The percentages used herein are calculated based upon 5,268,708 shares of Common Stock outstanding immediately following the September 4, 2025 closing of the issuer's registered direct offering as described in "Item 1 - Explanatory Note" above.

**(b)**
See rows (7) through (10) of the cover pages to this Schedule 13D/A for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

**(c)**
The Reporting Persons have not engaged in any transactions with respect to shares of the Common Stock during the past sixty (60) days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Accelmed Partners, L.P.

**Signature:** /s/ Uri Geiger

**Name/Title:** Uri Geiger/Managing Partner

**Date:** 09/05/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Accelmed Partners (GP), L.P.

**Signature:** /s/ Uri Geiger

**Name/Title:** Uri Geiger/Managing Partner

**Date:** 09/05/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Accelmed Growth Partners (AGP) Ltd.

**Signature:** /s/ Uri Geiger

**Name/Title:** Uri Geiger/Managing Partner

**Date:** 09/05/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Accelmed Growth Partners Management Ltd.

**Signature:** /s/ Uri Geiger

**Name/Title:** Uri Geiger/Managing Partner

**Date:** 09/05/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Uri Geiger

**Signature:** /s/ Uri Geiger

**Name/Title:** Uri Geiger, an individual

**Date:** 09/05/2025